Jordi Bruix

Summary

Affiliation: University of Barcelona
Country: Spain

Publications

  1. ncbi request reprint Focus on hepatocellular carcinoma
    Jordi Bruix
    BCLC Group, Liver Unit, Hospital Clinic, Villarroel 170, 08036 Barcelona, Spain
    Cancer Cell 5:215-9. 2004
  2. doi request reprint Current strategy for staging and treatment: the BCLC update and future prospects
    Alejandro Forner
    Barcelona Clinic Liver Cancer BCLC Group, Liver Unit, ICMDM, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
    Semin Liver Dis 30:61-74. 2010
  3. doi request reprint Hepatocellular carcinoma
    Alejandro Forner
    Barcelona Clinic Liver Cancer Group, Liver Unit, Hospital Clinic Barcelona, August Pi i Sunyer Biomedical Research Institute, University of Barcelona, Barcelona, Spain
    Lancet 379:1245-55. 2012
  4. ncbi request reprint Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma
    Alejandro Forner
    BCLC Group, Liver Unit, IDIBAPS, CIBERehd, Hospital Clinic, University of Barcelona, Spain
    Hepatology 47:97-104. 2008
  5. doi request reprint Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?
    Alejandro Forner
    Liver Unit, Barcelona Clinic Liver Cancer BCLC Group, Hospital Clinic, August Pi i Sunyer Institute of Biomedical Investigations, Biomedical Center for Research into Hepatic and Digestive Diseases CIBEREHD, University of Barcelona, Barcelona, Spain
    Cancer 115:616-23. 2009
  6. ncbi request reprint Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma
    Margarita Sala
    Liver Unit, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Hospital Clinic, University of Barcelona, Catalonia, Spain
    Hepatology 40:1352-60. 2004
  7. ncbi request reprint Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics
    Maria Varela
    Liver Unit, IMDM, Barcelona Clinic Liver Cancer BCLC Group, Hospital Clinic, CIBER HEPAD, University of Barcelona, Institut d Investigacions Biomediques August Pi i Sunyer, IDIBAPS, Barcelona, Spain
    J Hepatol 46:474-81. 2007
  8. doi request reprint Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial
    Jordi Bruix
    Barcelona Clinic Liver Cancer Group, Liver Unit, CIBERehd, Institut d Investigacions Biomédiques, August Pi i Sunyer, Hospital Clinic Barcelona, Barcelona, Spain
    J Hepatol 57:821-9. 2012
  9. doi request reprint Design and endpoints of clinical trials in hepatocellular carcinoma
    Josep M Llovet
    HCC Translational Research Lab, Barcelona Clinic Liver Cancer Group, Liver Unit, Hospital Clinic, CIBERehd, Institute for Biomedical Investigations August Pi Sunyer, Villarroel 170, 08036 Barcelona, Catalonia, Spain
    J Natl Cancer Inst 100:698-711. 2008
  10. pmc Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes
    Daniela Sia
    Barcelona Clínic Liver Cancer Group HCC Translational Research Laboratory, Liver Unit, Pathology Department, Institut d Investigacions Biomediques August Pi i Sunyer, Liver Unit, Hospital Clinic, Universitat de Barcelona, Barcelona, Catalonia, Spain
    Gastroenterology 144:829-40. 2013

Collaborators

Detail Information

Publications71

  1. ncbi request reprint Focus on hepatocellular carcinoma
    Jordi Bruix
    BCLC Group, Liver Unit, Hospital Clinic, Villarroel 170, 08036 Barcelona, Spain
    Cancer Cell 5:215-9. 2004
  2. doi request reprint Current strategy for staging and treatment: the BCLC update and future prospects
    Alejandro Forner
    Barcelona Clinic Liver Cancer BCLC Group, Liver Unit, ICMDM, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
    Semin Liver Dis 30:61-74. 2010
    ..Finally, patients at end-stage should merely receive palliative care...
  3. doi request reprint Hepatocellular carcinoma
    Alejandro Forner
    Barcelona Clinic Liver Cancer Group, Liver Unit, Hospital Clinic Barcelona, August Pi i Sunyer Biomedical Research Institute, University of Barcelona, Barcelona, Spain
    Lancet 379:1245-55. 2012
    ..Research is active in the area of pathogenesis and treatment of hepatocellular carcinoma...
  4. ncbi request reprint Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma
    Alejandro Forner
    BCLC Group, Liver Unit, IDIBAPS, CIBERehd, Hospital Clinic, University of Barcelona, Spain
    Hepatology 47:97-104. 2008
    ..These results validate the American Association for the Study of Liver Disease (AASLD) guidelines...
  5. doi request reprint Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?
    Alejandro Forner
    Liver Unit, Barcelona Clinic Liver Cancer BCLC Group, Hospital Clinic, August Pi i Sunyer Institute of Biomedical Investigations, Biomedical Center for Research into Hepatic and Digestive Diseases CIBEREHD, University of Barcelona, Barcelona, Spain
    Cancer 115:616-23. 2009
    ..The current report provides an assessment of the agreement/concordance between both RECIST and the EASL guidelines for the evaluation of response to therapy...
  6. ncbi request reprint Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma
    Margarita Sala
    Liver Unit, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Hospital Clinic, University of Barcelona, Catalonia, Spain
    Hepatology 40:1352-60. 2004
    ..Accordingly, initial complete tumor necrosis should be considered a relevant therapeutic target irrespective of tumor size and liver function...
  7. ncbi request reprint Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics
    Maria Varela
    Liver Unit, IMDM, Barcelona Clinic Liver Cancer BCLC Group, Hospital Clinic, CIBER HEPAD, University of Barcelona, Institut d Investigacions Biomediques August Pi i Sunyer, IDIBAPS, Barcelona, Spain
    J Hepatol 46:474-81. 2007
    ..This study assesses the safety, pharmacokinetics and efficacy of transarterial chemoembolization using drug eluting beads (DEB), an embolizing device that slowly releases chemotherapy to decrease systemic toxicity...
  8. doi request reprint Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial
    Jordi Bruix
    Barcelona Clinic Liver Cancer Group, Liver Unit, CIBERehd, Institut d Investigacions Biomédiques, August Pi i Sunyer, Hospital Clinic Barcelona, Barcelona, Spain
    J Hepatol 57:821-9. 2012
    ..In a comprehensive series of exploratory subgroup analyses, data from the SHARP trial were analyzed to discern if baseline patient characteristics influenced the efficacy and safety of sorafenib...
  9. doi request reprint Design and endpoints of clinical trials in hepatocellular carcinoma
    Josep M Llovet
    HCC Translational Research Lab, Barcelona Clinic Liver Cancer Group, Liver Unit, Hospital Clinic, CIBERehd, Institute for Biomedical Investigations August Pi Sunyer, Villarroel 170, 08036 Barcelona, Catalonia, Spain
    J Natl Cancer Inst 100:698-711. 2008
    ..These surrogate markers may help to enrich study populations and maximize the cost-benefit ratio of trial execution. Design and conduct of phase 3 trials should be coordinated by centers with appropriate expertise in HCC...
  10. pmc Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes
    Daniela Sia
    Barcelona Clínic Liver Cancer Group HCC Translational Research Laboratory, Liver Unit, Pathology Department, Institut d Investigacions Biomediques August Pi i Sunyer, Liver Unit, Hospital Clinic, Universitat de Barcelona, Barcelona, Catalonia, Spain
    Gastroenterology 144:829-40. 2013
    ..We performed an integrative genomic analysis of ICC samples from a large series of patients...
  11. doi request reprint Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma
    Silvia Tremosini
    Liver Unit, Barcelona Clinic Liver Cancer BCLC Group, Hospital Clinic Barcelona, IDIBAPS, University of Barcelona, Spain
    Gut 61:1481-7. 2012
    ..The aim of this study is to assess prospectively the diagnostic accuracy of a panel of markers (GPC3, HSP70, GS) for the diagnosis of HCC in patients with cirrhosis with a small (5-20 mm) nodule detected by ultrasound screening...
  12. doi request reprint New drugs for the treatment of hepatocellular carcinoma
    Eveline Boucher
    BCLC Group, Liver Unit, Hospital Clinic, IDIBAPS, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, University of Barcelona, Barcelona, Spain
    Liver Int 29:148-58. 2009
    ..In the next years, efforts should be directed to identifying genomic and proteomic profiling that will help us to assess the prognosis and to define what treatment benefits whom, ultimately giving way to personalized medicine...
  13. doi request reprint Medical treatments: in association or alone, their roles and their future perspectives: the Western experience
    Maria Reig
    BCLC Group, Liver Unit, Centro de Investigación Biomédica en Red de Hepatología y Enfermedades Digestivas, IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Villarroel 170, Barcelona 08036, Spain
    J Hepatobiliary Pancreat Sci 17:420-1. 2010
    ..Sorafenib has changed the management of HCC, opening the path to combination therapies for patients at advanced stages and to evaluation as an adjuvant for those in earlier evolutionary stages...
  14. ncbi request reprint The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma
    Josep M Llovet
    Liver Unit, Digestive Disease Institute, IDIBAPS, Hospital Clinic, University of Barcelona, Catalonia, Spain
    Liver Transpl 10:S115-20. 2004
    ..Finally, patients with end-stage disease should receive only palliative treatment to avoid unnecessary suffering...
  15. doi request reprint Treatment of early hepatocellular carcinoma: Towards personalized therapy
    Silvia Tremosini
    BCLC Group, Liver Unit, CIBERehd, IDIBAPS, Hospital Clinic, Barcelona, Spain
    Dig Liver Dis 42:S242-8. 2010
    ..We briefly reviewed therapeutic management for early HCC, taking into account that any recommendation should be delivered in the clinical setting and based on an individualised evaluation of each patient...
  16. ncbi request reprint p27(Kip1) is an independent predictor of recurrence after surgical resection in patients with small hepatocellular carcinoma
    Carolina Armengol
    Barcelona Clinic Liver Cancer BCLC Group, Liver Unit, Digestive Disease Institute, Hospital Clinic, Institut d Investigacio Biomedica August Pi i Sunyer IDIBAPS, University of Barcelona, Villarroel 170, 08036 Barcelona, Catalonia, Spain
    J Hepatol 38:591-7. 2003
    ..3+/-7 years, 30 males, 44 Child-Pugh's A, 30 HCV-positive) with small hepatocellular carcinoma (HCC, size: 3.1+/-1.5cm, 40 solitary at pathological examination)...
  17. doi request reprint Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma
    Josep M Llovet
    Barcelona Clinic Liver Cancer Group, Liver Unit, CIBERehd, Institut d Investigacions Biomédiques, August Pi i Sunyer, Hospital Clinic Barcelona, Barcelona, Spain
    Clin Cancer Res 18:2290-300. 2012
    ..One of the objectives of the phase III, randomized, controlled Sorafenib HCC Assessment Randomized Protocol (SHARP) trial was to explore the ability of plasma biomarkers to predict prognosis and therapeutic efficacy...
  18. ncbi request reprint MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation
    Marta Burrel
    Radiology Department, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Hospital Clinic, University of Barcelona, Catalonia, Spain
    Hepatology 38:1034-42. 2003
    ..In conclusion, MRA has a high diagnostic accuracy for HCC > or =10 mm and is more sensitive than triphasic helical CT in nodules sized 10 to 20 mm. MRA is the optimal technique for HCC staging prior to curative therapies...
  19. ncbi request reprint Applicability of adult-to-adult living donor liver transplantation
    Antoni Rimola
    Liver Unit, Hospital Clinic, Villarroel 170, 08036 Barcelona, Spain
    J Hepatol 43:104-9. 2005
    ..We report the first data in a European center of the process leading to this procedure from the first moment the patients were informed about it...
  20. doi request reprint Novel advancements in the management of hepatocellular carcinoma in 2008
    Josep M Llovet
    Barcelona Clinic Liver Cancer BCLC Group, Liver Unit, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, CIBERehd, Hospital Clinic, Villarroel 170, 08036 Barcelona, Catalonia, Spain
    J Hepatol 48:S20-37. 2008
    ..Now, the research effort faces other areas of unmet need, such as the adjuvant setting of resection/local ablation and combination therapies...
  21. ncbi request reprint Chemoembolization for hepatocellular carcinoma
    Jordi Bruix
    BCLC Group, Liver Unit, IDIBAPS, Hospital Clinic, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain
    Gastroenterology 127:S179-88. 2004
    ..The analysis of efficacy in these trials should be adjusted for prognostic factors, such as the presence of symptoms, Child-Pugh class, and segmental vascular invasion...
  22. ncbi request reprint Selection of candidates with HCC for transplantation in the MELD era
    Margarita Sala
    Barcelona Clinic Liver Cancer Group, Liver Unit, Hospital Clinic, University of Barcelona, Barcelona, Spain
    Liver Transpl 10:S4-9. 2004
    ..3%. 5. Priority policies have to be developed and refined to provide a fair and effective distribution of cadaveric organs...
  23. ncbi request reprint High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation
    Margarita Sala
    Liver Unit, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Hospital Clinic, University of Barcelona, Catalonia, Spain
    Liver Transpl 10:1294-300. 2004
    ..In conclusion, this policy is clinically effective and could further improve the outcome of resected patients...
  24. doi request reprint Management of HCC
    Carlos Rodriguez de Lope
    Barcelona Clinic Liver Cancer Group, Liver Unit, ICMDM, Hospital Clinic, IDIBAPS, University of Barcelona, Spain
    J Hepatol 56:S75-87. 2012
    ..In this article we review the current management in HCC and the new advances in this field...
  25. ncbi request reprint Treatment of hepatocellular carcinoma: is there an optimal strategy?
    Maria Varela
    Barcelona Clinic Liver Cancer Group, Liver Unit, Digestive Disease Institute, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, Villarroel 170, Barcelona, Spain
    Cancer Treat Rev 29:99-104. 2003
    ..Finally, patients with end-stage disease with heavily impaired liver function (Child-Pugh class C) or severe physical impairment (performance status 3-4) die within 6 months and should receive only symptomatic treatment...
  26. doi request reprint Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma
    Jordi Rimola
    BCLC Group Radiology Department, Hospital Clinic, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Institut d Investigacions Biomédiques August Pi y Sunyer, University of Barcelona, Barcelona, Spain
    Hepatology 50:791-8. 2009
    ..If washout is not registered, a biopsy should be mandatory for diagnosis...
  27. ncbi request reprint Preoperative evaluation of biliary anatomy in adult live liver donors with volumetric mangafodipir trisodium enhanced magnetic resonance cholangiography
    Juan R Ayuso
    Department of Radiology, Centre de Diagnostic per la Imatge Clinic, Institut Clinic de Malalties Digestives, Hospital Clinic, Institut d Investigacions Biomediques August PiI Sunyer, University of Barcelona, Barcelona, Spain
    Liver Transpl 10:1391-7. 2004
    ..002). In conclusion, Mn-DPDP-enhanced MRC is highly accurate in depicting the biliary duct anatomy and can be used preoperatively for surgical planning in LDLT...
  28. ncbi request reprint Treatment of hepatocellular carcinoma
    Alejandro Forner
    Liver Unit, Institut de Malalties Digestives i Metaboliques, BCLC Group, IDIPAPS, Hospital Clinic, University of Barcelona, C Villarroel 170, E 08036 Barcelona, Spain
    Crit Rev Oncol Hematol 60:89-98. 2006
    ..Finally, the patients with severe cancer-related symptoms or great tumor burden belong to the terminal stage and only benefit from symptomatic treatment...
  29. ncbi request reprint Abdominal drainage after liver resection for hepatocellular carcinoma in cirrhotic patients: a randomized controlled study
    Josep Fuster
    Department of Surgery, Hospital Clinic, University of Barcelona, Spain
    Hepatogastroenterology 51:536-40. 2004
    ..The objective of our study is to assess the usefulness of intra-abdominal drainage after liver resection for hepatocellular carcinoma in cirrhotic patients...
  30. ncbi request reprint Orthotopic implantation of human hepatocellular carcinoma in mice: analysis of tumor progression and establishment of the BCLC-9 cell line
    Carolina Armengol
    BCLC Group, Liver Unit, Digestive Disease Institute, Hospital Clinic, Institut d Investigacio Biomedica August Pi i Sunyer IDIBAPS, Barcelona, Spain
    Clin Cancer Res 10:2150-7. 2004
    ....
  31. pmc Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma
    Augusto Villanueva
    HCC Translational Research Laboratory, Barcelona Clinic Liver Cancer Group, Institut d Investigacions Biomediques August Pi i Sunyer, Liver Unit, Hospital Clinic, Barcelona, Spain
    Gastroenterology 140:1501-12.e2. 2011
    ..We evaluated gene expression signatures associated with outcome in a large cohort of patients with early stage (Barcelona-Clinic Liver Cancer 0/A), single-nodule HCC and heterogeneity of signatures within tumor tissues...
  32. ncbi request reprint Prognosis of hepatocellular carcinoma
    Josep M Llovet
    Barcelona Clinic Liver Cancer BCLC Group, Liver Unit, Institut de Malalties Digestives, Hospital Clínic Institut d Investigacions Biomèdiques August Pi i Sunyer IDIBAPS, University of Barcelona, Catalonia, Spain
    Hepatogastroenterology 49:7-11. 2002
    ..In addition to predicting prognosis, the staging system should also guide the selection of treatment and this is the major advantage of the classification applied in the Barcelona-Clinic Liver Cancer Group...
  33. ncbi request reprint Liver transplantation in hepatocellular carcinoma
    Josep Fuster
    Barcelona Clinic Liver Cancer BCLC Group, Department of Surgery, Digestive Disease Institute, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Hospital Clinic, University of Barcelona, Villaroel 170, 08036 Barcelona, Catalonia, Spain
    Transpl Int 18:278-82. 2005
    ..The development of adult living donor liver transplantation has proved to be a good alternative in this type of patients even if they do not fulfill the conventional criteria...
  34. doi request reprint Metabolic risk factors are a major comorbidity in patients with cirrhosis independent of the presence of hepatocellular carcinoma
    Amelia J Hessheimer
    BCLC Group, Liver Unit, Hospital Clinic, IDIBAPS, Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas CIBERehd, University of Barcelona, Catalonia, Spain
    Eur J Gastroenterol Hepatol 22:1239-44. 2010
    ..Recent studies have identified cases of hepatocellular carcinoma (HCC) arising in cryptogenic cirrhosis and proposed that many of them may be attributable to nonalcoholic fatty liver disease (NAFLD)...
  35. ncbi request reprint Prognostic prediction in patients with hepatocellular carcinoma
    Margarita Sala
    Liver Unit, Hospital Clinic, University of Barcelona, Institut d Investigacions Biomediques August Pi i Sunyer, 08036 Barcelona, Spain
    Semin Liver Dis 25:171-80. 2005
    ..It considers tumor stage, liver functional status, physical status, and cancer-related symptoms and, by dividing patients into early, intermediate, advanced, and end-stage categories, provides a link to treatment indication...
  36. doi request reprint Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C
    Jordi Bruix
    BCLC Group, Liver Unit, Hospital Clinic of Barcelona, University of Barcelona, IDIBAPS, Centro de Investigación Biomédica en Red de Hepatología y Enfermedades Digestivas, Barcelona, Spain
    Gastroenterology 140:1990-9. 2011
    ..We investigated the incidence of clinical events among participants of the Evaluation of PegIntron in Control of Hepatitis C Cirrhosis (EPIC)3 program...
  37. doi request reprint Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design
    Maria Reig
    Barcelona Clinic Liver Cancer BCLC Group, Liver Unit, Hospital Clinic Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd, Barcelona, Spain
    Hepatology 58:2023-31. 2013
    ..89 [1.62-5.15], respectively), definitive sorafenib interruption 2.48 [1.54-4.01], and TTP 3.39 [1.89-6.1]. The presence of NEH 2.42 [1.32-4.44] is also an independent predictor of OS and PPS in patients with radiologic progression...
  38. ncbi request reprint Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial
    Josep M Llovet
    Liver Unit, Digestive Disease Institute, Hospital Clinic, University of Barcelona, Barcelona, Spain
    Lancet 359:1734-9. 2002
    ..There is no standard treatment for unresectable hepatocellular carcinoma. Arterial embolisation is widely used, but evidence of survival benefits is lacking...
  39. ncbi request reprint Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival
    Josep M Llovet
    Barcelona Clinic Liver Cancer Group, Liver Unit, Digestive Disease Institut, Institut d Investigacions Biomediques August Pi i Sunyer, Hospital Clinic, Catalonia, Spain
    Hepatology 37:429-42. 2003
    ..In conclusion, chemoembolization improves survival of patients with unresectable HCC and may become the standard treatment. Treatment with tamoxifen does not modify the survival of patients with advanced disease...
  40. doi request reprint Angiogenesis in liver disease
    Mercedes Fernandez
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic IDIBAPS, University of Barcelona, Barcelona, Spain
    J Hepatol 50:604-20. 2009
    ....
  41. doi request reprint The size of the problem: clinical algorithms
    Alejandro Forner
    Barcelona Clinic Liver Cancer Group, Liver Unit, Hospital Clinic Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain
    Dig Dis 31:95-103. 2013
    ..Further efforts are needed to improve the survival of this lethal neoplasia. ..
  42. ncbi request reprint Contrast-enhanced power Doppler sonography and helical computed tomography for assessment of vascularity of small hepatocellular carcinomas before and after percutaneous ablation
    Ramon Vilana
    Radiology Department, Institut d Investigacions Biomediques August Pi i Sunyer, Hospital Clinic, University of Barcelona, Calle Villarroel, 170, 08036 Barcelona, Spain
    J Clin Ultrasound 31:119-28. 2003
    ..We compared the usefulness of Levovist-enhanced power Doppler imaging (PDI) and helical CT in the depiction of tumor vascularity before and after percutaneous ablation of small hepatocellular carcinomas (HCCs)...
  43. pmc IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage
    Victoria Tovar
    HCC Translational Laboratory, BCLC Group, Liver Unit and Pathology Department, Hospital Clinic, CIBERehd, IDIBAPS, C Villarroel 170, Catalonia, Spain
    J Hepatol 52:550-9. 2010
    ..We analyzed the underlying molecular mechanisms of IGF signaling activation in early hepatocellular carcinoma (HCC; BCLC class 0 or A) and assessed novel targeted therapies blocking this pathway...
  44. ncbi request reprint Hepatitis B virus and hepatocellular carcinoma
    Jordi Bruix
    BCLC Group, Liver Unit, Digestive Disease Institute, Hospital Clinic, IDIBAPS, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain
    J Hepatol 39:S59-63. 2003
  45. ncbi request reprint Hepatocellular carcinoma
    Josep M Llovet
    Barcelona Clinic Liver Cancer Group, Liver Unit, Digestive Disease Institute, IDIBAPS, Hospital Cli nic i Provincial, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain
    Lancet 362:1907-17. 2003
    ..Meta-analysis shows that only chemoembolisation improves survival in well-selected patients with unresectable HCC...
  46. doi request reprint Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors
    Elba Llop
    Hepatic Hemodynamic Laboratory, Liver Unit, University of Barcelona, Spain
    J Hepatol 56:103-8. 2012
    ..Liver stiffness (LS) evaluation by transient elastography might non-invasively identify CSPH. We investigated the usefulness of LS predicting CSPH in patients with compensated cirrhosis and potentially resectable liver tumors...
  47. ncbi request reprint Hepatocellular carcinoma in the setting of liver transplantation
    Maria Varela
    Barcelona Clinic Liver Cancer BCLC Group, Liver Unit, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain
    Liver Transpl 12:1028-36. 2006
  48. ncbi request reprint Expected developments in hepatology
    Xavier Forns
    Liver Unit, Hospital Clinic, Institut d Investigaciones Biomèdiques August Pi i Sunyer, University of Barcelona, Spain
    Best Pract Res Clin Gastroenterol 16:957-70. 2002
    ..The risk factors and primary, secondary and tertiary prevention of the condition are also analysed. Finally, the development of new therapeutic strategies for hepatocellular carcinoma is evaluated by evidence-based studies...
  49. ncbi request reprint Prognostic prediction and treatment strategy in hepatocellular carcinoma
    Jordi Bruix
    Barcelona Clinic Liver Cancer BCLC Group, Liver Unit, Digestive Disease Institute, Hospital Clinic i Provincial, Villaroel 170, 08036 Barcelona, Catalonia, Spain
    Hepatology 35:519-24. 2002
  50. ncbi request reprint Chemoembolization for intermediate HCC: is there proof of survival benefit?
    Alejandro Forner
    Barcelona Clinic Liver Cancer BCLC Group, Liver Unit, Hospital Clinic Barcelona, IDIBAPS, University of Barcelona, Spain
    J Hepatol 56:984-6. 2012
    ..Hepatocellular carcinoma (HCC) results in more than 600,000 deaths per year. Transarterial embolisation(TAE) and transarterial chemoembolisation (TACE) have become standard loco-regional treatments for unresectable HCC...
  51. ncbi request reprint Transarterial chemoembolization for patients with hepatocellular carcinoma
    Alejandro Forner
    Barcelona Clinic Liver Cancer BCLC Group, Liver Unit, IMDM, Hospital Clinic, IDIBAPS, CIBERehd, University of Barcelona, Barcelona, Spain
    Hepatol Res 37:S230-7. 2007
    ..Further randomized controlled trials are needed to assess the best chemotherapeutic agent and the ideal re-treatment schedule...
  52. ncbi request reprint Treatment strategies for hepatocellular carcinoma in cirrhosis
    W Scott Helton
    Department of Surgery, University of Illinois, Chicago, IL, USA
    J Gastrointest Surg 7:401-11. 2003
  53. ncbi request reprint Identification of novel tumor markers in hepatitis C virus-associated hepatocellular carcinoma
    Maria W Smith
    Department of Microbiology, School of Medicine, and Washington National Primate Research Center, University of Washington, Seattle, Washington 98195, USA
    Cancer Res 63:859-64. 2003
    ..Thus, high throughput methods coupled with high-order statistical analyses may result in the development of new diagnostic tools for liver malignancies...
  54. ncbi request reprint Prognostic assessment and evaluation of the benefits of treatment
    Jordi Bruix
    Barcelona Clinic Liver Cancer Group, Liver Unit, Digestive, Disease Institute, Barcelona, Catalonia Spain
    J Clin Gastroenterol 35:S138-42. 2002
    ..Finally, those with severe liver function or health status impairment constitute the end-stage category and cannot be expected to survive more than 1 year...
  55. ncbi request reprint Unresectable hepatocellular carcinoma: meta-analysis of arterial embolization
    Josep M Llovet
    Radiology 230:300-1; author reply 301-2. 2004
  56. ncbi request reprint HCC surveillance: who is the target population?
    Jordi Bruix
    Hepatology 37:507-9. 2003
  57. ncbi request reprint Liver transplantation for hepatocellular carcinoma: Foucault pendulum versus evidence-based decision
    Jordi Bruix
    Liver Transpl 9:700-2. 2003
  58. ncbi request reprint Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma
    Sigal Kremer-Tal
    Division of Liver Diseases, Mount Sinai School of Medicine, New York, NY 10029, USA
    Hepatology 40:1047-52. 2004
    ..In conclusion, we propose that KLF6 is deregulated by loss and/or mutation in HCC, and its inactivation may contribute to pathogenesis in a significant number of these tumors...
  59. ncbi request reprint Clinical management of hepatic malignancies: ferucarbotran-enhanced magnetic resonance imaging versus contrast-enhanced spiral computed tomography
    Riccardo Lencioni
    Department of Radiology, University of Pisa, Pisa, Italy
    Dig Dis Sci 50:533-7. 2005
    ..0167). Ferucarbotran-enhanced MR imaging is superior to spiral CT in clinical management of patients with suspected hepatic malignancy...
  60. ncbi request reprint Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma
    Elisa Wurmbach
    Mount Sinai Liver Cancer Program, Division of Hematology Oncology, Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA
    Hepatology 45:938-47. 2007
    ....
  61. ncbi request reprint Expanded criteria for hepatocellular carcinoma through down-staging prior to liver transplantation: not yet there
    Josep M Llovet
    Mount Sinai Liver Cancer Program, Divisions of Liver Disease and Recanati Miller Transplantation Institute, Department of Surgery, Mount Sinai School of Medicine, New York, NY 10029, USA
    Semin Liver Dis 26:248-53. 2006
    ..Only a few small studies with heterogeneous target populations and treatments applied are available. The results of these studies are inconsistent and do not provide compelling evidence to accept down-staging as a standard of care...
  62. ncbi request reprint Locoregional treatment for hepatocellular carcinoma: From clinical exploration to robust clinical data, changing standards of care
    Alejandro Forner
    Hepatology 47:5-7. 2008
  63. ncbi request reprint A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis
    Josep M Llovet
    Mount Sinai Liver Cancer Program, Department of Medicine, Mount Sinai School of Medicine, New York 10029, USA
    Gastroenterology 131:1758-67. 2006
    ..Small liver nodules approximately 2 cm are difficult to characterize by radiologic or pathologic examination. Our aim was to identify a molecular signature to diagnose early hepatocellular carcinoma (HCC)...
  64. ncbi request reprint Diagnosis and staging of hepatocellular carcinoma prior to transplantation: expertise or failure
    Maria Varela
    Liver Transpl 12:1445-7. 2006
  65. doi request reprint Sorafenib in advanced hepatocellular carcinoma
    Josep M Llovet
    Barcelona Clinic Liver Cancer Group, Institut d Investigacions Biomediques August Pi i Sunyer, Centro de Investigaciones en Red de Enfermedades Hepáticas y Digestivas Hospital Clínic Barcelona, Barcelona
    N Engl J Med 359:378-90. 2008
    ..A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and Raf may be effective in hepatocellular carcinoma...
  66. pmc Focal gains of VEGFA and molecular classification of hepatocellular carcinoma
    Derek Y Chiang
    Department of Medical Oncology and Center for Cancer Genome Discovery, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Res 68:6779-88. 2008
    ..Furthermore, the prevalence of VEGFA high-level gains in multiple tumor types suggests indications for clinical trials of antiangiogenic therapies...
  67. pmc Molecular targeted therapies in hepatocellular carcinoma
    Josep M Llovet
    Mount Sinai Liver Cancer Program, Division of Liver Diseases, Mount Sinai School of Medicine, New York, NY, USA
    Hepatology 48:1312-27. 2008
    ..Ultimately, a molecular classification of HCC based on genome-wide investigations and identification of patient subclasses according to drug responsiveness will lead to a more personalized medicine...
  68. ncbi request reprint Hepatocellular carcinoma in the United States. Lessons from a population-based study in Medicare recipients
    Maria Varela
    J Hepatol 44:8-10. 2006
  69. ncbi request reprint Management of hepatocellular carcinoma
    Jordi Bruix
    BCLC Group Liver Unit Hospital Clínic, University of Barcelona, Institut d Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain
    Hepatology 42:1208-36. 2005
  70. ncbi request reprint Diagnosis of Small HCC
    Jordi Bruix
    Gastroenterology 129:1364. 2005
  71. pmc Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation
    Sigal Kremer-Tal
    Division of Liver Diseases and Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA
    J Hepatol 46:645-54. 2007
    ..Hepatocellular carcinoma (HCC) has the most rapidly rising cancer incidence in the US and Europe. The KLF6 tumor suppressor is frequently inactivated in HCC by loss-of-heterozygosity (LOH) and/or mutation...